Ciro Indolfi


Affiliation: Magna Graecia University
Country: Italy


  1. Eyileten C, Wicik Z, De Rosa S, Mirowska Guzel D, Soplinska A, Indolfi C, et al. MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke-A Comprehensive Review and Bioinformatic Analysis. Cells. 2018;7: pubmed publisher
    ..Among our most interesting findings, miR-19a-3p is the most widely modulated miRNA across all selected ontologies and might be proposed as novel biomarker in IS to be tested in future studies. ..
  2. Indolfi C, Iaconetti C, Gareri C, Polimeni A, De Rosa S. Non-coding RNAs in vascular remodeling and restenosis. Vascul Pharmacol. 2018;: pubmed publisher
  3. Indolfi C, Passafaro F, Sorrentino S, Spaccarotella C, Mongiardo A, Torella D, et al. Hand Laser Perfusion Imaging to Assess Radial Artery Patency: A Pilot Study. J Clin Med. 2018;7: pubmed publisher
    ..0; p < 0.001), with an optimal diagnostic cutoff at 0.2 RPI. LPI is a reliable diagnostic technique for RAO, offering the advantages of being quick and simple to perform. ..
  4. Indolfi C, Mongiardo A, Spaccarotella C, Torella D, Caiazzo G, Polimeni A, et al. The instantaneous wave-free ratio (iFR) for evaluation of non-culprit lesions in patients with acute coronary syndrome and multivessel disease. Int J Cardiol. 2015;178:46-54 pubmed publisher
    ..147) nor the time interval from the acute event (p=0.550) significantly influenced the concordance of iFR with FFR. The iFR is a promising method for the assessment of non-culprit lesion severity in patients with acute coronary syndrome. ..
  5. Serra R, De Franciscis S, Grande R, Butrico L, Perri P, Indolfi C, et al. Endovascular repair for acute traumatic transection of the descending thoracic aorta: experience of a single centre with a 12-years follow up. J Cardiothorac Surg. 2015;10:171 pubmed publisher
    ..The protocol was registered at a public trials registry, (trial identifier NCT02376998 ). ..
  6. De Rosa S, Indolfi C. Circulating microRNAs as Biomarkers in Cardiovascular Diseases. Exp Suppl. 2015;106:139-149 pubmed publisher
  7. Iaconetti C, Sorrentino S, De Rosa S, Indolfi C. Exosomal miRNAs in Heart Disease. Physiology (Bethesda). 2016;31:16-24 pubmed publisher
    ..This review addresses the functional role played by exosomal miRNAs in heart disease and their potential use as new biomarkers. ..
  8. Iaconetti C, Gareri C, Polimeni A, Indolfi C. Non-coding RNAs: the "dark matter" of cardiovascular pathophysiology. Int J Mol Sci. 2013;14:19987-20018 pubmed publisher
    ..This review outlines the current knowledge of the different ncRNA classes and summarizes their role in cardiovascular development and disease. ..
  9. De Rosa S, Chiefari E, Salerno N, Ventura V, D Ascoli G, Arcidiacono B, et al. HMGA1 is a novel candidate gene for myocardial infarction susceptibility. Int J Cardiol. 2017;227:331-334 pubmed publisher

More Information


  1. Sorrentino S, Iaconetti C, De Rosa S, Polimeni A, Sabatino J, Gareri C, et al. Hindlimb Ischemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery. Sci Rep. 2018;8:761 pubmed publisher
    ..Thus, hindlimb ischemia affects negative carotid remodeling increasing neointima formation after injury, while systemic antagonizzation of miR-16 is able to prevent these negative effects. ..
  2. Spaccarotella C, Mongiardo A, De Rosa S, Indolfi C. Transcatheter aortic valve implantation in patients at intermediate surgical risk. Int J Cardiol. 2017;243:161-168 pubmed publisher
  3. Polimeni A, De Rosa S, Sabatino J, Sorrentino S, Indolfi C. Impact of intracoronary adenosine administration during primary PCI: A meta-analysis. Int J Cardiol. 2016;203:1032-41 pubmed publisher
    ..04) and long-term (RR = 0.61 [0.39–0.95] p = 0.03). This is the first meta-analysis demonstrating a clinical benefit for IC adenosine in hard endpoints, such as adverse cardiovascular events, in patients undergoing primary PCI. ..
  4. Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, et al. Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 2015;107:522-33 pubmed publisher
    ..By luciferase reporter assay, we validated the transcription factor FoxO4 as a direct target of miR-23b in VSMCs. We identify miR-23b as a novel regulator of VSMC phenotypic switch in vitro and following vascular injury in vivo. ..
  5. Gareri C, Iaconetti C, Sorrentino S, Covello C, de Rosa S, Indolfi C. miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1. J Mol Biol. 2017;429:1817-1828 pubmed publisher
    ..Thus, miR-125a-5p in this context inhibits PDGF-BB pathway and is therefore a potential regulator of VSMCs phenotypic switch. ..
  6. De Rosa S, Polimeni A, Petraco R, Davies J, Indolfi C. Diagnostic Performance of the Instantaneous Wave-Free Ratio: Comparison With Fractional Flow Reserve. Circ Cardiovasc Interv. 2018;11:e004613 pubmed publisher
    ..Finally, iFR and FFR have similar diagnostic efficiency for detection of ischemia-inducing stenoses when tested against a third comparator. ..
  7. Sorrentino S, De Rosa S, Ambrosio G, Mongiardo A, Spaccarotella C, Polimeni A, et al. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc Disord. 2015;15:169 pubmed publisher
    ..Our results strongly support the maintenance of balloon inflation for at least 30" during BVS deployment to achieve optimal scaffold expansion and minimize the occurrence of residual stenosis. ..
  8. Indolfi C, Mongiardo A, Spaccarotella C, Caiazzo G, Torella D, De Rosa S. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation. Circ Cardiovasc Imaging. 2014;7:755-7 pubmed publisher
  9. De Rosa S, Polimeni A, Sabatino J, Indolfi C. Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis. BMC Cardiovasc Disord. 2017;17:240 pubmed publisher
    ..Hence, a large part of patients with unprotected left main coronary artery disease can be managed equally well by means of both these revascularization strategies. ..
  10. Polimeni A, Anadol R, Münzel T, Indolfi C, De Rosa S, Gori T. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs. BMC Cardiovasc Disord. 2017;17:147 pubmed publisher
    ..6% vs 0.1%, OR 4.03, 95% CI 1.37 to 11.82; p = 0.01) was higher with BRS compared with EES. BRS may be associated with worse two-years clinical outcomes compared with EES in patients with coronary artery disease. ..